Speaker(s): 

Ronald Zsido, Pharmacy Intern Technician, Staff Member, Geisinger - has nothing to disclose.

Moderator(s): 

Sarah F. Hale, PharmD, BCPPS, Director of Pharmacy, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Summarize key clinical findings comparing 0.3mg versus 0.5mg intramuscular epinephrine for anaphylaxis.

• Assess safety considerations between using the 0.3mg versus 0.5mg intramuscular epinephrine dose.

• Evaluate the implications of the study results compared to current practice across Geisinger.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Sarah F. Hale, PharmD, Brian Simpkins, PharmD, Jessica Milheim, CPhT, Clara Bishay, PharmD, and Simran Kaur, PharmD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPAA compliant. 

Commercial Support for this Session

None.